Domača stranME • NASDAQ
add
23andMe Holding Co.
3,11 $
Po zaprtju:(3,54 %)+0,11
3,22 $
Konec trgovanja: 22. nov., 18:26:25 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
3,23 $
Dnevni razpon
2,99 $ - 3,21 $
Letni razpon
2,66 $ - 20,20 $
Tržna kapitalizacija
74,94 mio. USD
Povprečni obseg
404,88 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 44,07 mio. | −11,86 % |
Stroški poslovanja | 81,33 mio. | −17,18 % |
Čisti dohodek | −59,10 mio. | 21,48 % |
Čista dobičkovnost prihodkov | −134,11 | 10,91 % |
Earnings per share | — | — |
EBITDA | −54,96 mio. | 21,06 % |
Efektivna davčna stopnja | 0,07 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 126,60 mio. | −50,62 % |
Skupna sredstva | 318,94 mio. | −60,19 % |
Skupne obveznosti | 217,01 mio. | 23,31 % |
Celoten lastniški kapital | 101,93 mio. | — |
Shares outstanding | 26,12 mio. | — |
Razmerje P/B | 0,82 | — |
Donosnost sredstev | −42,89 % | — |
Donosnost kapitala | −75,30 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −59,10 mio. | 21,48 % |
Denar iz dejavnosti | −40,93 mio. | 28,34 % |
Denar iz naložb | −2,70 mio. | 2,63 % |
Denar iz financiranja | 260,00 tis. | −83,68 % |
Neto sprememba denarnih sredstev | −43,37 mio. | 25,18 % |
Prost denarni tok | −12,82 mio. | 59,90 % |
Vizitka
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Generalni direktor
Datum ustanovitve
apr. 2006
Sedež organizacije
Spletno mesto
Zaposleni
571
